Figure 3. Drug potency validation studies revealed.
(A) Ryuvidine to be selective against HPV-negative cell lines (** p=0.003) and (B) MK-1775 to be selective against HPV-positive cell lines (* p=0.03).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.